Compugen (NASDAQ:CGEN – Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02, FiscalAI reports. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The firm had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $1.28 million.
Compugen Price Performance
CGEN opened at $1.96 on Monday. The business has a 50 day simple moving average of $2.25 and a two-hundred day simple moving average of $2.29. The firm has a market capitalization of $185.32 million, a price-to-earnings ratio of 5.16 and a beta of 2.85. Compugen has a one year low of $1.43 and a one year high of $3.23.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Compugen in a report on Monday, October 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Compugen in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $5.00.
Get Our Latest Stock Analysis on Compugen
About Compugen
Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.
Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.
Read More
- Five stocks we like better than Compugen
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
